1. Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy
2. Center for Interstitial and Rare Lung Diseases, Department of Pneumology and Critical Care Medicine, Thoraxklinik, University of Heidelberg, Heidelberg, Germany, Member of the German Center for Lung Research
3. Catholic University of the Sacred Heart, Rome, Italy
4. University of British Columbia, Vancouver, British Columbia, Canada
5. Assistance Publique-Hôpitaux de Paris, Avicenne Hospital University, Bobigny, France
6. Interstitial Lung Diseases Center of Excellence, Department of Pulmonology, St. Antonius Hospital, Nieuwegein, the Netherlands
7. Division of Heart & Lungs, University Medical Center Utrecht, Utrecht, the Netherlands
8. Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
9. Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany; and
10. Unit for Interstitial Lung Diseases, Department of Respiratory Medicine, University Hospitals Leuven, Leuven, Belgium